Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook

被引：2

作者：

Zhou, Wenhao ^{[1
]}

Lu, Xiaojun ^{[1
]}

Tian, Feng ^{[2
]}

Luo, Qianming ^{[3
]}

Zhou, Weihang ^{[3
]}

Yang, Siyuan ^{[3
]}

Li, Wenxuan ^{[4
]}

Yang, Yongjun ^{[4
]}

Shi, Minfeng ^{[5
]}

Zhou, Tie ^{[1
]}

机构：

[1] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Dept Urol, Shanghai 200434, Peoples R China

[2] Shanghai Eighth Peoples Hosp, Dept Urol, Shanghai 200235, Peoples R China

[3] Tongji Univ, Sch Med, Shanghai 200092, Peoples R China

[4] Naval Med Univ, Coll Clin Med, Shanghai 200433, Peoples R China

[5] Naval Med Univ, Changhai Hosp, Reprod Ctr, Shanghai 200433, Peoples R China

来源：

VACCINES | 2024年 / 12卷 / 12期

关键词：

prostate cancer; cancer vaccines; immunotherapy; combination therapies; PERSONALIZED PEPTIDE VACCINATION; ANDROGEN DEPRIVATION THERAPY; PHASE I/II TRIAL; SIPULEUCEL-T; CELLULAR IMMUNOTHERAPY; IMMUNOLOGICAL EFFICACY; CLINICAL-TRIAL; DNA VACCINES; II TRIAL; ANTIGEN;

D O I：

10.3390/vaccines12121384

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Prostate cancer is a prevalent cancer in elderly men, and immunotherapy has emerged as a promising treatment approach in recent years. The aim of immunotherapy is to stimulate the body's immune system to target and destroy cancer cells. Cancer vaccines that are highly specific, safe, and capable of creating long-lasting immune responses are a key focus in cancer immunotherapy research. Despite progress in clinical trials showing positive results, the practical use of cancer vaccines still encounters various obstacles. The complexity of the immune microenvironment and variations in the immune systems of individual patients have hindered the progress of research on prostate cancer vaccines. This review examines the history and mechanisms of cancer vaccines, summarizes recent clinical research findings, and explores future directions in the development of prostate cancer vaccines.

引用

页数：15

共 80 条

[41] A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer [J].

Noguchi, Masanori ;

Moriya, Fukuko ;

Koga, Noriko ;

Matsueda, Satoko ;

Sasada, Tetsuro ;

Yamada, Akira ;

Kakuma, Tatsuyuki ;

Itoh, Kyogo .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (02) :151-160

[42] T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer [J].

Obradovic, Aleksandar Z. ;

Dallos, Matthew C. ;

Zahurak, Marianna L. ;

Partin, Alan W. ;

Schaeffer, Edward M. ;

Ross, Ashley E. ;

Allaf, Mohamad E. ;

Nirschl, Thomas R. ;

Liu, David ;

Chapman, Carolyn G. ;

O'Neal, Tanya ;

Cao, Haiyi ;

Durham, Jennifer N. ;

Guner, Gunes ;

Baena-Del Valle, Javier A. ;

Ertunc, Onur ;

De Marzo, Angelo M. ;

Antonarakis, Emmanuel S. ;

Drake, Charles G. .

CLINICAL CANCER RESEARCH, 2020, 26 (13) :3182-3192

[43] Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD) [J].

Olson, Brian M. ;

Bradley, Eric S. ;

Sawicki, Thomas ;

Zhong, Weixiong ;

Ranheim, Erik A. ;

Bloom, Jordan E. ;

Colluru, Viswa T. ;

Johnson, Laura E. ;

Rekoske, Brian T. ;

Eickhoff, Jens C. ;

McNeel, Douglas G. .

PROSTATE, 2017, 77 (07) :812-821

[44] IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) [J].

Pachynski, Russell K. ;

Morishima, Chihiro ;

Szmulewitz, Russell ;

Harshman, Lauren ;

Appleman, Leonard ;

Monk, Paul ;

Bitting, Rhonda L. ;

Kucuk, Omer ;

Millard, Frederick ;

Seigne, John D. ;

Fling, Steven P. ;

Maecker, Holden T. ;

Duault, Caroline ;

Ramchurren, Nirasha ;

Hess, Bruce ;

D'Amico, Leonard ;

Lacroix, Andreanne ;

Kaiser, Judith C. ;

Morre, Michel ;

Gregoire, Anne ;

Cheever, Martin ;

Yu, Evan Y. ;

Fong, Lawrence .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)

[45] A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer [J].

Pavlenko, M ;

Roos, AK ;

Lundqvist, A ;

Palmborg, A ;

Miller, AM ;

Ozenci, V ;

Bergman, B ;

Egevad, L ;

Hellström, M ;

Kiessling, R ;

Masucci, G ;

Wersäll, P ;

Nilsson, S ;

Pisa, P .

BRITISH JOURNAL OF CANCER, 2004, 91 (04) :688-694

[46] Tumor heterogeneity [J].

Pe'er, Dana ;

Ogawa, Seishi ;

Elhanani, Ofer ;

Keren, Leeat ;

Oliver, Trudy G. ;

Wedge, David .

CANCER CELL, 2021, 39 (08) :1015-1017

[47] Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response [J].

Perez-Banos, Amarilis ;

Gleisner, Maria Alejandra ;

Flores, Ivan ;

Pereda, Cristian ;

Navarrete, Mariela ;

Araya, Juan Pablo ;

Navarro, Giovanna ;

Quezada-Monras, Claudia ;

Tittarelli, Andres ;

Salazar-Onfray, Flavio .

BRITISH JOURNAL OF CANCER, 2023, 129 (04) :572-585

[48] Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer [J].

Podrazil, Michal ;

Horvath, Rudolf ;

Becht, Etienne ;

Rozkova, Daniela ;

Bilkova, Pavla ;

Sochorova, Klara ;

Hromadkova, Hana ;

Kayserova, Jana ;

Vavrova, Katerina ;

Lastovicka, Jan ;

Vrabcova, Petra ;

Kubackova, Katerina ;

Gasova, Zdenka ;

Jarolim, Ladislav ;

Babjuk, Marek ;

Spisek, Radek ;

Bartunkova, Jirina ;

Fucikova, Jitka .

ONCOTARGET, 2015, 6 (20) :18192-18205

[49] Strategies in DNA vaccine for melanoma cancer [J].

Rezaei, Tayebeh ;

Davoudian, Elham ;

Khalili, Saeed ;

Amini, Mohammad ;

Hejazi, Maryam ;

de la Guardia, Miguel ;

Mokhtarzadeh, Ahad .

PIGMENT CELL & MELANOMA RESEARCH, 2021, 34 (05) :869-891

[50] Adoptive cell transfer as personalized immunotherapy for human cancer [J].

Rosenberg, Steven A. ;

Restifo, Nicholas P. .

SCIENCE, 2015, 348 (6230) :62-68

← 1 2 3 4 5 6 7 8 →